Viewing Study NCT02114502


Ignite Creation Date: 2025-12-25 @ 4:02 AM
Ignite Modification Date: 2026-06-16 @ 4:06 PM
Study NCT ID: NCT02114502
Status: WITHDRAWN
Last Update Posted: 2014-07-11
First Post: 2014-04-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
Sponsor: M.D. Anderson Cancer Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myeloma View
None Multiple myeloma View
None MM View
None Refractory View
None Relapsed View
None Stem Cell Transplant View
None SCT View
None Carfilzomib View
None SAHA View
None Vorinostat View
None Suberoylanilide Hydroxamic Acid View
None MSK-390 View
None Zolinza View
None Gemcitabine View
None Gemcitabine Hydrochloride View
None Gemzar View
None Busulfan View
None Busulfex View
None Myleran View
None Palifermin View
None Kepivance View
None Dexamethasone View
None Decadron View
None Melphalan View
None Alkeran View
None Caphosol View
None Glutamine View
None Enterex View
None Glutapak-10 View
None NutreStore View
None Resource View
None GlutaSolve View
None Sympt-X G.I. View
None Sympt-X View
None Pyridoxine View